地榆升白片预防宫颈癌患者TP新辅助化疗方案所致骨髓抑制的效果及对外周血象的影响  

Effects of Diyushengbai Tablet in Preventing Myelosuppression Induced by TP Neoadjuvant Chemotherapy and on Peripheral Hemogram in Patients with Cervical Cancer

作　　者：牟大英[1] 黄露[1] 路祥会[1] 何德斌 MOU Daying;HUANG Lu;LU Xianghui;HE Debin(Dept.of Gynecology,the First People’s Hospital of Zunyi,Guizhou Zunyi 563100,China)

机构地区：[1]遵义市第一人民医院妇科

出　　处：《中国医院用药评价与分析》2019年第11期1306-1308,共3页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：贵州省科技计划项目(No.黔科合SY字[2011]3042号)

摘　　要：目的:探讨地榆升白片预防宫颈癌患者TP(紫杉醇+顺铂)新辅助化疗方案所致骨髓抑制的效果及对外周血象的影响。方法:选取2014年1月至2017年12月遵义市第一人民医院收治的宫颈癌患者80例,根据随机数字表法分为观察组和对照组,每组40例。所有患者均进行支持治疗,对照组患者采用TP新辅助化疗方案治疗,观察组患者在对照组的基础上加用地榆升白片治疗。3个疗程后,观察两组患者骨髓抑制程度、外周血象情况、临床疗效及不良反应发生情况。结果:化疗3个疗程后,对照组Ⅲ-Ⅳ度骨髓抑制患者所占比例为35.0%(14/40),明显高于观察组的12.5%(5/40),差异有统计学意义(P<0.05);观察组患者的白细胞计数、血红蛋白及血小板水平明显高于对照组,差异均有统计学意义(P<0.05);观察组、对照组患者的缓解率分别为85.0%(34/40)、82.5%(33/40),差异无统计学意义(P>0.05)。治疗期间,两组患者不良反应发生率的差异无统计学意义(P>0.05),且未见严重不良反应发生。结论:地榆升白片联合TP新辅助化疗方案治疗宫颈癌的效果较好,可有效减轻患者骨髓抑制情况,提高血细胞计数,促进造血功能恢复。OBJECTIVE: To probe into the effects of Diyushengbai tablet in preventing myelosuppression induced by TP(paclitaxel+cisplatin) neoadjuvant chemotherapy and on peripheral hemogram in patients with cervical cancer. METHODS: 80 patients with cervical cancer admitted into the First People’s Hospital of Zunyi from Jan. 2014 to Dec. 2017 were selected and divided into observation group and control group via random number table, with 40 cases in each group. All patients were received supportive treatment, the control group was given TP neoadjuvant chemotherapy, while the observation group was given Diyushengbai tablets based on the control group. After 3 treatment courses, the myelosuppression, peripheral hemogram, clinical efficacy and incidences of adverse drug reactions of both groups were observed. RESULTS: After 3 courses of chemotherapy, the proportion of patients with myelosuppression in grade Ⅲ-Ⅳ of control group was 35.0%(14/40), which was significantly higher than that of the observation group(12.5%, 5/40), with statistically significant difference(P<0.05);the white blood cell count, hemoglobin and blood platelet levels of observation group were significantly higher than those of the control group, with statistically significant differences(P<0.05);the remission rates of observation group and control group were respectively 85.0%(34/40) and 82.5%(33/40), the difference had no statistical significance(P>0.05). During treatment, there was no statistical significance in difference of incidences of adverse drug reactions between two groups(P>0.05), and no severe adverse drug reaction occurred. CONCLUSIONS: The efficacy of Diyushengbai tablets combined with TP neoadjuvant chemotherapy in treatment of cervical cancer, which can effectively relieve myelosuppression, improve blood cell count and promote the recovery of hematopoietic function.

关 键 词：宫颈癌 地榆升白片 骨髓抑制 外周血象 

分 类 号：R932[医药卫生—生药学]